Interleukin-2 (IL-2) Market Summary
The Interleukin-2 market is witnessing a significant surge driven by growing interest in cancer immunotherapy, autoimmune disease management, and next-generation cytokine engineering. In 2023, the IL-2 market size was highest in the US among the 7 Major Markets (7MM), accounting for approximately USD 6 million, which is further expected to increase substantially by 2034. This growth trajectory is underpinned by a robust clinical pipeline, increased regulatory activity, and rising disease burden across key indications including melanoma, atopic dermatitis, and non-small cell lung cancer (NSCLC).
The 7MM includes the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Across these geographies, the United States continues to dominate the market share, driven by advanced healthcare infrastructure, early adoption of novel immunotherapies, and a high volume of ongoing Interleukin-2 Clinical Trials.
Unlock comprehensive insights into the Interleukin-2 market for Melanoma – access our full report and accelerate your strategic decision-making today.
Interleukin-2 Overview
Interleukin-2 (IL-2) is a cytokine – a small protein that plays a pivotal role in the immune system by regulating the growth, activation, and differentiation of T-cells. It is produced primarily by activated CD4+ T-helper cells, although it can also be secreted by CD8+ T-cells, natural killer (NK) cells, and other immune cells. IL-2 is essential for the expansion and survival of T-cells during immune responses, particularly in response to infections or the presence of tumors. It promotes the activation and proliferation of both helper T-cells and cytotoxic T-cells.
IL-2 also plays a critical role in immune self-regulation by promoting the differentiation of regulatory T-cells (Tregs), which help prevent autoimmune reactions and maintain immune tolerance. Due to its immune-enhancing properties, IL-2 has been utilized therapeutically in immunotherapy, especially in the treatment of certain cancers like melanoma and renal cell carcinoma.
Despite challenges related to systemic toxicity and short half-life, Interleukin-2 remains a promising tool in cancer immunotherapy. Ongoing research aims to refine its applications by minimizing adverse effects and maximizing therapeutic potential across cancer, autoimmune diseases, and transplant rejection.
Interleukin-2 Epidemiology
The epidemiology covered in the report provides historical as well as forecasted data segmented by Total Diagnosed Prevalent Cases of Selected Indications for Interleukin-2 in the 7MM, Indication-wise Eligible Cases, and Indication-wise Treated Cases, covering the United States, EU4, the United Kingdom, and Japan from 2020 to 2034.
Key Findings from Interleukin-2 Epidemiological Analyses and Forecast:
- Among all prevalent cases across selected indications, Atopic Dermatitis recorded the highest burden with approximately 38,412,058 cases in the 7MM in 2020
- In the US, Atopic Dermatitis accounted for the highest number of prevalent cases at approximately 16,014,815, while Aplastic Anemia recorded the lowest with 776 cases in 2020
- In EU4 and the UK, Germany accounted for the highest number of Atopic Dermatitis treated cases with approximately 1,069,104 cases in 2020
- In Japan, the total number of ALS-eligible cases was approximately 11,150 in 2020
Interleukin-2 Market Recent Developments and Breakthroughs
The Interleukin-2 landscape has seen considerable momentum through late 2025 and early 2026, with several companies reporting meaningful clinical and financial milestones:
- January 2026 – HCW Biologics: Announced first patient dosing in a Phase 1 clinical trial of HCW9302 at The Ohio State University Wexner Medical Center. The study evaluates safety and tolerability in patients with Alopecia Areata. HCW9302 is an injectable immunotherapeutic designed to stimulate Tregs to suppress the autoimmune response, aiming to promote hair regrowth in patients with this chronic autoimmune skin disorder.
- November 2025 – Werewolf Therapeutics: Reported Q3 2025 financial results and provided a business update on its PREDATOR® platform, advancing lead “INDUKINE” candidates WTX-124 and WTX-330 through clinical trials for solid tumors. The platform is engineered to deliver potent cytokines specifically to the tumor microenvironment while minimizing systemic toxicity.
- December 2025 – Nektar Therapeutics: Presented new data from the REZOLVE-AD Phase 2b study investigating rezpegaldesleukin (REZPEG) for moderate-to-severe atopic dermatitis. REZPEG, a first-in-class Treg cell stimulator, demonstrated significant improvements in skin clearance and itch reduction compared to placebo, with durable efficacy noted even after treatment discontinuation – supporting its potential as a disease-modifying therapy.
Interleukin-2 Drug Analysis
The drug chapter of the Interleukin-2 market report encompasses a detailed analysis of marketed and emerging pipeline drugs, including those in Phase I, Phase I/II, Phase II, and Phase III development. It covers clinical trial details, pharmacological mechanisms, agreements and collaborations, patent status, and the latest news associated with each candidate.
Marketed Interleukin-2 Drugs
LYMPHIR/REMITORO (denileukin diftitox) – Eisai and Citius Oncology
LYMPHIR is an immune therapy indicated for relapsed or refractory CTCL, specifically for Stage I–III disease after at least one prior systemic treatment. It is a recombinant fusion protein combining the IL-2 receptor binding domain with diphtheria toxin fragments, enabling it to selectively target IL-2 receptors on malignant cells. Upon receptor binding, diphtheria toxin fragments enter the cell and inhibit protein synthesis, leading to targeted cell death.
- Approved by the US FDA in August 2024; expected launch in January 2025
- Approved by MHLW (Japan) in March 2021
Emerging Interleukin-2 Drugs
Soquelitinib (CPI-818) – Corvus Pharmaceuticals
Soquelitinib is an investigational oral small molecule designed to selectively inhibit ITK (IL-2-inducible T-cell kinase), an enzyme predominantly expressed in T-cells that plays a central role in T-cell and NK cell function. It is currently in a randomized, placebo-controlled Phase I trial in patients with atopic dermatitis. The first cohort (100 mg, twice daily) has completed enrollment with no safety signals reported. The second cohort (200 mg, once daily) is currently enrolling. Soquelitinib has also shown the ability to prevent T-cell exhaustion – a critical limitation in current CAR-T therapies. In November 2024, new preclinical data highlighted its potential in treating systemic sclerosis in Fra-2 transgenic mice.
ILT-101 – ILTOO Pharma
ILT-101 is a ready-to-use, injectable liquid formulation of low-dose IL-2, designed specifically to address patient needs across a wide range of autoimmune, inflammatory, and central nervous system disorders. ILTOO Pharma continues to make significant regulatory and clinical progress and is currently providing ILT-101 on a compassionate-use basis for patients who participated in clinical trials while pursuing formal approval pathways.
Leading Interleukin-2 Companies
The competitive landscape of Interleukin-2 Companies developing therapies is expansive and spans large pharmaceutical organizations to specialized biotech innovators. Key players include:
- Mural Oncology, Corvus Pharmaceuticals, Philogen, Merck, Nektar Therapeutics, Cue Biopharma, Krystal Biotech, ILTOO Pharma, Innovent, Regeneron Pharmaceuticals, R2T Biopharma (XEME Biopharma), GI Innovation, AstraZeneca, BioNTech, Medicenna Therapeutics, Ascendis Pharma, Sanofi/Synthorx, Cugene/AbbVie, Deka Biosciences, Dragonfly Therapeutics, Werewolf Therapeutics, Xilio Therapeutics, Bioniz Therapeutics/Equillium, Asher Bio, Synthekine, Anaveon, Aulos Bioscience, Selecxine/ProBio, Hoffmann-La Roche, TILT Biotherapeutics, and others
These Interleukin-2 Companies are collectively investing in engineering next-generation IL-2 variants with improved receptor selectivity, reduced toxicity, and optimized pharmacokinetics to address the shortcomings of first-generation therapies.
Access our detailed Interleukin-2 market analysis for Renal Cell Carcinoma and leverage data-driven insights to strengthen your oncology portfolio strategy today.
Conclusion
The global Interleukin-2 market stands at an exciting inflection point, propelled by scientific innovation, clinical breakthroughs, and a deepening understanding of cytokine biology. With a diverse portfolio of Interleukin-2 Drugs spanning marketed therapies and a robust pipeline of candidates in early-to-late stage Interleukin-2 Clinical Trials, the field is rapidly evolving beyond its early limitations. The convergence of precision engineering, combination immunotherapy strategies, and expanding indications – from CTCL and melanoma to atopic dermatitis and ALS – positions IL-2 as a cornerstone of next-generation immunotherapy. Stakeholders across the biopharma ecosystem stand to benefit significantly from continued investment in this space through 2034.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
